Arcturus Therapeutics And CSL Announce European Medicines Agency Validates Marketing Authorization Application For ARCT-154 Vaccine To Prevent COVID-19
Portfolio Pulse from Happy Mohamed
Arcturus Therapeutics (NASDAQ:ARCT) and CSL (ASX:CSL) announced that the European Medicines Agency (EMA) has validated the marketing authorization application for ARCT-154, a next-generation mRNA vaccine for COVID-19. The EMA submission is based on successful Phase 3 clinical results, with an approval decision expected by the European Commission in 2024. ARCT-154 showed 56.6% efficacy for prevention of symptomatic COVID-19 and 95.3% efficacy for prevention of severe COVID-19.
September 05, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics' ARCT-154 vaccine has been validated by the EMA, with an approval decision expected in 2024. This could potentially boost the company's stock in the short term.
The validation of the marketing application for ARCT-154 by the EMA is a significant milestone for Arcturus Therapeutics. This news could potentially increase investor confidence in the company, leading to a short-term boost in the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
CSL, in partnership with Arcturus Therapeutics, has had its ARCT-154 vaccine validated by the EMA. An approval decision is expected in 2024, which could positively impact CSL's stock in the short term.
The validation of the marketing application for ARCT-154 by the EMA is a significant milestone for CSL. This news could potentially increase investor confidence in the company, leading to a short-term boost in the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100